SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: S-3
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea0266812-s3_synergy.htm

Chunk 16 of 26
Word Count: 1480
Character Count: 9571

Document Content:

and litigation to prosecute such claims. These forward-looking statements involve numerous risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results of operations or the results of other matters that we anticipate could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Business,” “Regulation” and other sections included or incorporated by reference in this prospectus supplement. You should thoroughly read this prospectus supplement and the documents incorporated herein by reference with the understanding that our actual future results may be materially different from and worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements.

The forward-looking statements
made in this prospectus supplement relate only to events or information as of the date on which the statements are made in or incorporated
by reference in this prospectus supplement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to
reflect the occurrence of unanticipated events. You should read this prospectus supplement, the documents incorporated by reference into
this prospectus supplement and the documents we have filed as exhibits to the registration statement, of which this prospectus supplement
forms a part, completely and with the understanding that our actual future results may be materially different from what we expect.

S-iii

PROSPECTUS SUPPLEMENT SUMMARY

This summary highlights
selected information contained elsewhere in this prospectus supplement. This summary does not contain all the information that you should
consider before investing in our Company. You should carefully read the entire prospectus supplement, including all documents incorporated
by reference herein. In particular, attention should be directed to our “Risk Factors,” “Information With Respect to
the Company,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the
financial statements and related notes thereto contained herein or otherwise incorporated by reference hereto, before making an investment
decision.

Our Company

We are a provider of consumer health care, beauty, and lifestyle products.
Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement (this study
was performed independently and is not related to any FDA-approved investigational new drug (IND) application) that has been shown
to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products
to help women achieve their nutrition and weight management goals. For the year ended December 31, 2024, FOCUSfactor represented
88% of our net revenue and Flat Tummy was 12%. For the nine months ended September 30, 2025, FOCUSfactor represented 86% of our net revenue
and Flat Tummy represented 14%. Our products are sold through some of the nation’s leading club, mass drug, and other retailers
such as Costco, Amazon.com, Walmart, Walgreens, CVS, BJ’s Wholesale Club, Publix Supermarkets, The Vitamin Shoppe, Target.com, H-E-B,
Meijer, and Albertson’s. Additionally, we have expanded into Canada and the United Kingdom.

We built our brand portfolio
through strategic acquisitions. We acquired the FOCUSfactor brand in January 2015 for cash consideration of $6.0 million, including
earnout. In November 2015, we acquired our second marquee brand, Flat Tummy, for AUD 10.0 million (approximately $7.0 million),
using a mix of cash and stock. Our capital structure following the acquisitions of our key brands in 2015 has been highly levered, and
our focus has been on paying our debt and, as a result, we do not have the resources to grow our business. We have grown our FOCUSfactor
brand from 3 SKUs at acquisition to over 34 SKUs, and our Flat Tummy Brand from 1 SKU to 13 SKUs. We use the term SKU, or stock-keeping unit,
to refer to a product with a unique UPC (Universal Product Code), which is the barcode used to identify products.

Our growth from 2022 to the present was driven by expanded distribution
of our FOCUSfactor product line to some of our major retailers, such as Costco, CVS and Walmart, among others. This expansion included
SKUs within our FOCUSfactor vision line as well as focus and energy Ready-to-Drink (RTD). As a result, net revenue for the year ended
December 31, 2024 was $34.8 million, a decrease of $8 million, or 19%, compared to net revenue for the year ended December 31,
2023 of $42.8 million. Net revenue for the nine months ended September 30, 2025 was $24.3 million, a decrease of $0.3 million, or
1% compared to net revenue of $24.6 million for the nine months ended September 30, 2024. FOCUSfactor net revenue decreased 2% from $21.3
million for the nine months ended September 30, 2024 to $20.8 million for the nine months ended September 30, 2025. FOCUSfactor net revenue
for the year ended December 31, 2024 was $30.8 million, a 17.0% decrease from FOCUSfactor net revenue for the year ended December 31,
2023 of $37.2 million. During the nine months ended September 30, 2025 we also had revenue from a license agreement of $2.9 million
related to expansion in selected foreign markets, which we anticipate to be an ongoing source of revenue.

Our Brands

Our flagship brand, FOCUSfactor, is a brain health nutritional supplement
with over 24 years of history and a clinically-tested formula (this study was performed independently and is not related to
any FDA-approved IND application) comprised of a proprietary blend of key brain supporting ingredients along with vitamins, minerals,
and other nutrients. We believe FOCUSfactor is the only product in its category whose entire formula has been shown to support memory,
concentration and focus. Our FOCUSfactor brand consists of over 34 SKUs and is sold primarily through leading retailers in the United States,
including Costco, Walmart, Amazon.com, Walgreens, CVS, Meijer, and Albertson’s in addition to selling direct to consumer through
the FOCUSfactor website. Across three of our key partners, we have increased the number of SKUs sold through the retailer from the single
SKU available at the beginning of our relationship in 2015 or 2016. In addition, we have increased our presence in retail locations for
these key partners, resulting in a significant increase in points of distribution, being the number of SKUs multiplied by the number of
retail locations for each retailer. We have also expanded the brand internationally into Canada (2020), the UK (2023) and we anticipate
being in Mexico in the fourth quarter of 2025 and in Australia and Asia in 2026.

FOCUSfactor has expanded into
the beverage market with its focus plus energy RTD. According to Zion Research in January 2024, the beverage market is large
($176 billion in 2022) and growing (projected 8.6% CAGR covering eight years from 2022 through 2030) with an expanding range
of functional benefits such as energy, hydration, cognition/focus, weight loss, gut health and immunity. Examples such as Celsius and
Beyond Raw offer dual-benefit products that deliver fat burning plus energy while C4 Smart Energy and FocusAid deliver focus plus
energy. Additionally, consumers are looking for not only refreshing drinks but health perks such as zero sugar and low-calorie drinks.
This consumer shift in preferences towards more functional benefits can be seen in the evolution of the energy RTD category where originally
competitors like Red Bull and Monster delivered conventional energy, then the category offered more performance energy products with added
vitamins and amino acids in products such as Reign and C4 Performance to products with more natural energy characteristics and then to
the dual-benefit energy products that we see today.

FOCUSfactor is well-positioned to
capitalize on the evolving energy RTD category (U.S. sales of $19.2 billion in 2023 and a CAGR of 6.3% from 2018 to 2023, according
to Euromonitor in December 2023) with its new focus plus energy RTD. We believe this represents a major growth opportunity,
with our dual-benefit RTD formula offering both focus and energy behind a 24+ year brand with strong heritage and awareness in the
area of brain health. The FOCUSfactor brand name clearly communicates the differentiation benefit of adding focus to energy. The FOCUSfactor
formula does not have to rely as heavily on caffeine as other brands such as Celsius, Bang, Reign and C4, as its formula is a balanced
blend of vitamins, cognitive nutrients and caffeine all in a zero sugar, low calorie, great-tasting drink. The brand also delivers
a significant value relative to many competitors. Additionally, FOCUSfactor has long-term relationships with large retailers where
it has an established presence, which will assist in market penetration for its RTD products. FOCUSfactor is looking to attract both existing
consumers of supplement products (typically consumers over age 50) to RTDs as well as a younger demographic (aged 18-49).